Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects
Brief Summary: The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.


Options:
A: Intervention Type: BIOLOGICAL; Name: Influenza virus vaccine (Fluviral); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Saline placebo; Assigned to Arm(s): N/A
B: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA) | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA) | Arm Label: A/H1N1 Vaccine Group 3; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 3 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
C: Arm Label: CCI; Type: EXPERIMENTAL; Interventions: Biological: Cell culture-derived influenza vaccine | Arm Label: IVV; Type: EXPERIMENTAL; Interventions: Biological: Egg-derived influenza virus vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Cell culture-derived influenza vaccine; Assigned to Arm(s): CCI | Intervention Type: BIOLOGICAL; Name: Egg-derived influenza virus vaccine; Assigned to Arm(s): IVV | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 4: Placebo: Intramuscular; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Group 3: Placebo: Nasal; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Group 1: FluMist™; Type: EXPERIMENTAL; Interventions: Biological: Cold-adapted live attenuated influenza virus vaccine, trivalent | Arm Label: Group 2: Fluzone®/Fluvirin; Type: EXPERIMENTAL; Interventions: Biological: Trivalent inactivated influenza vaccine | Intervention Type: BIOLOGICAL; Name: Cold-adapted live attenuated influenza virus vaccine, trivalent; Assigned to Arm(s): Group 1: FluMist™ | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 4: Placebo: Intramuscular | Intervention Type: BIOLOGICAL; Name: Trivalent inactivated influenza vaccine; Assigned to Arm(s): Group 2: Fluzone®/Fluvirin | Intervention Type: BIOLOGICAL; Name: Trivalent inactivated influenza vaccine; Assigned to Arm(s): Group 2: Fluzone®/Fluvirin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 3: Placebo: Nasal

Answer: C